Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Scadden
Harvard University, Department: Anatomy/cell Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Magenta Therapeutic
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
See attachment.
A defend and destroy approach to curing HIV
This proposal seeks to achieve a durable cure of HIV through the use of blood stem cells genetically engineered to be resistant to HIV infection. Combining this with novel approaches to less toxic transplant procedures may make stem cell transplant useful broadly. This proposal brings together a team of researchers who can create, test and prepare clinical grade products to move a 'defend and destroy' strategy against HIV to application in people. Project-001: Engineering stem and effector cells towards a functional HIV-1 cure Project Leader (PL): Derrick J. Rossi DESCRIPTION (as provided by applicant): The functional cure of the 'Berlin Patient' through transplantation of allogeneic CCR5?32 stem cells advocates for using gene-altered stem cells to confer lifetime protection against HIV-1 re-infection. Large-scale adoption of allogeneic transplantation of CCR5?32 stem cells is not possible however. The barriers to stem cell transplantation as a therapeutic option for HIV will be significantly lowered if gene-editing platforms could be used to safely and efficiently generate patient-specific CCR5 null CD34+ HSCs for autologous transplantation. At the same time, it is also clear that eradication of HIV reserves will be an important part of an effective and durable HIV cure. In this multidisciplinary proposal we will apply several cutting edge technologies including modified-mRNA and CRISPR/Cas9 gene-editing platforms to engineer CD34+ hematopoietic stem cells and CD8+ T-cells towards the goals generating HIV-resistant immune systems, and eradicating viral reserves.
Filed on January 09, 2019.
Tell us what you know about David Scadden's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Scadden filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Scadden | University of Tx Md Anderson Can Ctr | Conflict of Interest | Fate Therapeutics | $5,000 - $9,999 |
| David Scadden | University of Tx Md Anderson Can Ctr | Conflict of Interest | Fate Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.